Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Trial Profile

Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms S-TRAC; S-TRAC
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Oct 2017 This trial has been completed in Denmark (end date: 30 Aug 2017).
    • 23 Sep 2017 This trial has been completed in Spain (end date: 28 Aug 2017).
    • 19 Sep 2017 According to a Pfizer media release, FDA's Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-containing kidney).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top